SM17

BIOLOGICAL2 trials

Sponsors

SinoMab BioScience Ltd

Conditions

AsthmaAtopic DermatitisInflammatory Bowel Disease

Phase 1

A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects

CompletedNCT05332834

SinoMab BioScience LtdAsthma

Start: 2022-06-14End: 2023-09-26Updated: 2024-09-27

A Clinical Study to Evaluate SM17 in Healthy Participants

CompletedNCT07466940

SinoMab BioScience LtdAsthma, Atopic Dermatitis, Inflammatory Bowel Disease

Start: 2025-10-14End: 2026-02-03Updated: 2026-04-06

Related Papers

Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial

Frontiers in Immunology2024-12-095 citations

513 - Blockage of IL-25 pathway as a potential target therapy for atopic dermatitis

British Journal of Dermatology2024-02-011 citations